These questions concern your feelings over the past 4 weeks about **the skin condition that has bothered you the most**. Check the answer that comes closest to the way you have been feeling.

	NEVER	RARELY	SOMETIMES	OFTEN	ALL THE TIME
1. My skin hurts	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
2. My skin condition affects how well I sleep	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
3. I worry that my skin condition may be serious	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
4. My skin condition makes it hard to work or do hobbies	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
5. My skin condition affects my social life	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
6. My skin condition makes me feel depressed	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
7. My skin condition burns or stings	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
8. I tend to stay at home because of my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
9. I worry about getting scars from my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
10. My skin itches	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
11. My skin condition affects how close I can be with those I love	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
12. I am ashamed of my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
13. I worry that my skin condition may get worse	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
14. I tend to do things by myself because of my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
15. I am angry about my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
16. Water bothers my skin condition (bathing, washing hands)	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
17. My skin condition makes showing affection difficult	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
18. I worry about side-effects from skin medications / treatments	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
19. My skin is irritated	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
20. My skin condition affects my interactions with others	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
21. I am embarrassed by my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
22. My skin condition is a problem for the people I love	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
23. I am frustrated by my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
24. My skin is sensitive	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
25. My skin condition affects my desire to be with people	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
26. I am humiliated by my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
27. My skin condition bleeds	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
28. I am annoyed by my skin condition	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
29. My skin condition interferes with my sex life	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
30. My skin condition makes me tired	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
31. I worry about going outside because the sun might flare my disease	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
32. I am worried about my hair loss	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
33. My skin disease prevents me from doing outdoor activities	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
34. When talking to someone, I worry about what they may be thinking of me	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
35. My skin condition influences the clothes I wear	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
36. My skin condition affects my grooming practices (e.g., haircut, use of cosmetics)	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅
37. My skin condition affects my sun protection habits during recreation (e.g., limiting exposure time during sun peak hours, seeking shade, wearing a hat, long sleeves or pants)	☐ ₁	☐ ₂	☐ ₃	☐ ₄	☐ ₅

Abstract 253 Figure 1 The CLE-specific quality of life measure CLEQoL

254

IDENTIFICATION OF DAMAGE CLUSTERS IN SYSTEMIC LUPUS ERYTHEMATOSUS

¹Ga Young Ahn, ²Jiyoung Lee, ²Soyoung Won, ³Eunji Ha, ¹Hyoungyoung Kim, ¹Ji Soong Kim, ¹Juyeon Kang, ¹Bora Nam, ¹So-Young Bang, ⁴Seung Cheol Shim, ¹Hye-Soon Lee, ⁵Kwangwoo Kim, ¹Sang-Cheol Bae*. ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; ²Clinical Research Center for Rheumatoid Arthritis; ³Department of Biology, Kyung Hee University; ⁴Division of Rheumatology, Department of Internal medicine, Chungnam National University; ⁵Department of Biology, Kyung Hee University, Republic of Korea

10.1136/lupus-2019-lsm.254

Background Damage in SLE is an irreversible change of organ system results from SLE involvement or adverse effects of medications. Recently, the awareness and evidence of

subphenotypes in SLE has been increased. In this study, thus we are to identify damage clusters and compare organ damage involvement, demographic and clinical manifestations, mortality and weighted genetic risk score (GRS) between clusters.

Methods The study was conducted from Hanyang Bae lupus Cohort. Patients whose disease duration is less than 5 years were excluded to minimize potential confounding effects of disease duration. Patients were grouped into 3 clusters based on SLICC Damage Index (SDI) at last follow-up visit using K-mean cluster analysis. Comparison of characteristics between clusters were performed using ANOVA and Chi-square test.

Results A total number of 1130 patients were analyzed. Both the last follow-up visit, musculoskeletal damage was the most frequent damage domain followed by ocular, renal and

Abstract 254 Table 1 Comparison of disease activity, damage score and mortality between damage clusters

Variables	Cluster 1 (n=824)	Cluster 2 (n=195)	Cluster 3 (n=111)	P value
Age at SLE diagnosis	27.87±10.60	27.21±11.31	25.56±10.36	0.399
Female sex	774 (93.9) ^a	169 (86.7) ^c	102 (91.9)	0.002
Disease duration at last follow up, years	12.07±5.42 ^{ab}	14.96±6.05 ^c	14.06±5.84 ^c	<0.001
Weighted GRS	1.56±1.09	1.78±1.00	1.43±1.12	0.036 ^s
Adjusted Mean SLEDAI	3.96±2.21	5.40±2.94	4.20±2.94	<0.001
Mortality	20 (2.4)	11 (5.6)	16 (14.4)	<0.001
Damage involvement (at last follow-up)				
Ocular	0	113 (58.0)	16 (14.4)	<0.001
Neuropsychiatric	0	4 (2.1)	111 (100.0)	<0.001
Renal	0	108 (55.4)	11 (9.9)	<0.001
Pulmonary	60 (7.3)	20 (10.3)	19 (17.1)	0.002
Cardiovascular	26 (3.2)	13 (6.7)	3 (2.7)	0.055
Peripheral vascular	27 (3.3)	8 (4.1)	5 (4.5)	0.722
Gastrointestinal	8 (1.0)	3 (1.5)	3 (2.7)	0.024
Musculoskeletal	132 (16.0)	57 (29.2)	39 (35.1)	<0.001
Skin	31 (3.8)	10 (5.1)	7 (6.3)	0.367
Premature gonadal failure	0	5 (2.6)	4 (3.6)	<0.001
Diabetes Mellitus	22 (2.7)	16 (8.2)	6 (5.4)	0.001
Malignancy	47 (5.7)	7 (3.6)	3 (2.7)	0.237

^aSignificantly different from cluster 2.^bSignificantly different from cluster 3.^cSignificantly different from cluster 1.^{*}Continuous variables were compared using analysis of variance (ANOVA) and nominal variable (mortality) was compared using chi-square test.^sTukey's test showed there was no statistically significant difference between clusters.

neuropsychiatric damage. Three separate damage clusters were identified. Cluster 1 included 824 (72.9%) of patients. None of patients in cluster 1 was accompanied by ocular, neuropsychiatric, renal damage and premature gonadal failure. Patients in cluster 1 had significantly less pulmonary damage than cluster 3, significantly less diabetes mellitus than cluster 2, and significantly less musculoskeletal damage than two the other clusters. Cluster 2 (n=195, 17.3%) was represented by prevalent ocular (58.0%) and renal (55.4%) damage. Patients in cluster 2 had significantly more ocular, renal damage than two the other clusters. All the patients of cluster 3 (n=111, 9.8%) was accompanied by neuropsychiatric damage (100%). Patients in cluster 3 had significantly more musculoskeletal (35.1%) damage than two the other clusters. Age of SLE diagnosis and autoantibody positivity were similar among 3 clusters. Adjusted mean SLEDAI (AMS) was highest in cluster 2 (Mean ±SD, 6.7±4.8), and mortality was highest in cluster 3. Weighted GRS showed no significant difference between clusters.

Conclusions We classified patients by patterns of damage involvement (damage cluster) within a SLE cohort. Renal and neuropsychiatric damage were the two distinct domain of damage that classified patients into 3 clinically meaningful clusters. Patients in cluster 2 (prevalent renal and glucocorticoid associated damage) had the highest AMS. The highest mortality was recognized in cluster with prevalent neuropsychiatric damage. Therefore, we should be attentive to prevent renal and neuropsychiatric damage to improve the survival.

Funding Source(s): Comparison of demographic and clinical characteristics between damage clusters

255

RITUXIMAB THERAPY IN LUPUS NEPHRITIS RESISTANT TO CONVENTIONAL THERAPY: A SINGLE CENTER EXPERIENCE (CASE SERIES)

¹Berna Yurttaş, ²Bugra Egeli, ³Serdar Ugurlu*. ¹Cerrahpasa Medical Faculty, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa

10.1136/lupus-2019-lsm.255

Background Lupus nephritis(LN) can be a cause of morbidity and mortality. The treatment of lupus nephritis can be challenging in some patients who are resistant to conventional immunosuppressive treatment. There are case series showing the efficacy of rituximab on systemic lupus erythematosus (SLE) patients, but there are no randomized clinical trials. Therefore, we evaluated the efficacy and safety of rituximab treatment in LN patients in our clinic retrospectively.

Methods We evaluated LN patients who were followed and treated with at least one course of rituximab in our clinic between 2013–2018, retrospectively. We evaluated all of the patients before rituximab treatment and 3 months after the final rituximab course with 24 hour proteinuria. Remission was defined as proteinuria below 500 mg/day. Also, we evaluated the reason behind the cessation of rituximab during the follow-up whether it is a side effect or lack of efficacy.

Results Thirty-two patients (19 F, 13 M) were treated with rituximab. All of the patients had active lupus nephritis at initiation. Median of disease duration was 4 years. Diagnosis was proven by renal biopsy, except two patients, which is shown in table 1 of histological characteristics. Patients received an average of 4.2±3.8 courses. All patients were